CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI) Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how? Prevalence of Angina Among Primary Care Patients With Coronary Artery Disease Transition of Macrophages to Fibroblast-Like Cells in Healing Myocardial Infarction Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non–ST-Segment Elevation Myocardial Infarction Analysis of reperfusion time trends in patients with ST-elevation myocardial infarction across New York State from 2004 to 2012

Expert Opinion2021 Feb 16;105499.

JOURNAL:Pharmacol Res. Article Link

OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY SYNDROMES: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

M Banach, PE Penson, ACS EuroPath Central & South European Countries Project et al. Keywords: PCSK9 inhibitors; combination therapy; effectiveness; ezetimibe; safety; statins

Full Text PDF